With the objective of replacing cumbersome aerosol mist nebulizers, Nob Hill Therapeutics was founded to develop and market a compact, handheld, portable device designated DryNeb, a first-in-kind dry powder nebulizer to address large pulmonary drug delivery market opportunities. PI on funded NIH project is identified in various write-up as as principal and owner of another firm (Coelus LLC), where he facilitates early to late phase development of pharmaceutical IP and provides consulting services in integrated drug development strategies, toxicology, pharmacology, and hazard assessment. A pharmacologist, board certified toxicologist, ABT Board Member, and Fellow of the Academy of Toxicology Sciences (ATS). PI is indicated as on Nob Hill Therapeutics Boad of advisors - advising the firm's management on grant development and clinical trials.